Vertex’s VX-548 For Acute Pain May Be Right On Time For Market

Medicare Policy Change In 2025 Favors Non-Opioids

The company’s NaV1.8 inhibitor succeeded in Phase III acute pain trials and will be submitted for US FDA approval in mid-2024. It may reach the market in time for Medicare reimbursement changes favoring non-opioids.

Abdominoplasty plastic operation to reduce the abdomen and remove cellulite
VX-548 succeeded in Phase III abdominoplasty and bunionectomy studies • Source: Shutterstock

The closely watched Phase III clinical trials for Vertex Pharmaceuticals Incorporated’s NaV1.8 inhibitor VX-548 in the treatment of moderate-to-severe acute pain following abdominoplasty, bunionectomy and other procedures or events successfully met most of the three studies’ endpoints. As a result, the company plans to submit the drug for US Food and Drug Administration approval by mid-2024 and, if approved, it could reach the market in time for Medicare reimbursement changes favoring non-opioids.

Key Takeaways
  • VX-548 achieved statistical significance versus placebo on the primary endpoint in two Phase III studies and was deemed safe and effective in a Phase III single-arm trial in acute pain.

Vertex closed up 2.4% at $446.08 – a new all-time high – on 30 January when it reported the Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from R&D

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.